Akebia Therapeutics (AKBA) Gross Profit (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Gross Profit data on file, last reported at $41.3 million in Q1 2026.

• On a quarterly basis, Gross Profit fell 17.01% year-over-year to $41.3 million in Q1 2026; TTM through Mar 2026 was $188.3 million, a 30.99% increase from a year earlier, with the FY2025 full-year figure at $196.7 million, up 47.87% from the prior year.
• Gross Profit for Q1 2026 stood at $41.3 million, down from $45.1 million in the prior quarter.
• Over the last five years, Gross Profit for AKBA reached as high as $107.8 million in Q2 2022 and fell as low as -$23.0 million in Q1 2022.
• Historically, Gross Profit has averaged $36.4 million across 5 years, with a median of $35.1 million in 2024.
• On a YoY basis, Gross Profit climbed as much as 1042.91% in 2022 and fell as far as 186.22% in 2022.
• Year by year, Gross Profit stood at $32.2 million in 2022, then jumped by 44.63% to $46.5 million in 2023, then slipped by 24.49% to $35.1 million in 2024, then advanced by 28.3% to $45.1 million in 2025, then slipped by 8.5% to $41.3 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $41.3 million in Q1 2026, $45.1 million in Q4 2025, and $49.4 million in Q3 2025.